Snapshot from Jun 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Veracyte
Company

Veracyte

Tracked across 1 events · 21 articles · First seen May 29, 2026 · Last active Jun 02, 2026

Sentiment
75
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 75
Tech
Prosigna Test Reduces Chemotherapy for Breast Cancer
A groundbreaking clinical trial, OPTIMA, led by University College London and coordinated by the University of Warwick, has demonstrated that a genomic test called Prosigna can safely identify breast cancer patients who can avoid chemotherapy.…
Impact: Veracyte developed the Prosigna genomic test, which has been proven effective in guiding breast cancer treatment decisions, potentially increasing its market adoption and revenue.
May 29, 2026 · 21 articles
Key Actions (1)
95 Veracyte developed genomic testProsigna Test Reduces...
NEWSDESK
Track Veracyte live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.